MedPage Today

Stevens-Johnson Syndrome Support Lags After Hospital Discharge, Survivors Say

Survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) reported lasting sequelae with insufficient ...

New study reveals long-term impacts on Stevens-Johnson syndrome survivors

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) survivors encounter rare, life-threatening drug reactions ...
Medscape

SJS/TEN Survivors Face Physical, Psychological, and Social Challenges Years After Discharge

A US study finds that survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis face lasting physical, ...
News-Medical.Net on MSN

Study reveals long-term struggles after Stevens-Johnson syndrome and toxic epidermal necrolysis

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) survivors encounter rare, life-threatening drug reactions ...
European Medical Journal

Gaps in Long-Term Care of SJS/TEN Survivors

New findings reveal significant long-term challenges for SJS/TEN survivors and gaps in follow-up care. Learn more about the ...
The Citizen

Gumede siblings launch a joint crowdfunding camping to support fight against rare illnesses

Sabelo “Sabz” Gumede and his sister Charity “Shaz” Gumede have launched a joint crowdfunding campaign as they both battle ...
Medscape

High Mortality Rate Linked to Enfortumab Vedotin Skin Toxicity, No Added Risk From Checkpoint Inhibitors or Corticosteroids

Postmarket surveillance data revealed that enfortumab vedotin (EV) skin toxicity is associated with high hospitalization and ...
MedPage Today on MSNOpinion

What a Doctor Can See Is Only Part of the Story

By harnessing the relationship between neurons, neurotransmitters, and the skin barrier, neurocosmetics attempt to answer a ...
Targeted Oncology

FDA Grants Fast Track Designation to AVZO-103 for Urothelial Cancer

AVZO-103 has received fast track designation for treating urothelial cancer patients previously treated with enfortumab ...

Kyowa Kirin to Present New Research Highlighting Mogamulizumab’s Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting

Data to be shared during poster sessions on December 6 and 7, 2025Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), ...

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir ...

If PIFELTRO is coadministered with rifabutin, increase PIFELTRO dosage to one tablet twice daily (approximately 12 hours apart). Consult the full Prescribing Information prior to and during treatment ...